HER-2 SMASH

Basit Öğe Kaydı
dc.contributor.authorAlandag, Celal
dc.contributor.authorOzturk, Ayseguel
dc.contributor.authorYulak, Fatih
dc.contributor.authorInan, Zeynep Deniz Sahin
dc.contributor.authorKaraca, Mustafa
dc.contributor.authorLacin, Burak Batuhan
dc.contributor.authorAltun, Ahmet
dc.date.accessioned2025-05-04T16:47:27Z
dc.date.available2025-05-04T16:47:27Z
dc.date.issued2025
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractPurposeHuman epidermal growth factor-2 (HER-2) targeted drugs are used in only HER-2 overexpressed cancers. However, only a small portion of these cancer types are HER-2 overexpressed. In this study, we aimed to upregulate HER-2 receptors in MCF-7 breast cancer and HT-29 colon cancer cell cultures, which these cells are not HER-2 upregulated in natural status.MethodsWe used a 10-day non-cytotoxic lapatinib dose to upregulate HER-2 receptors. HER-2 levels of these cell lines were tested with ELISA and immunofluorescence tests before and after 10 days of lapatinib administration. After upregulation of HER-2, we administered trastuzumab, and T-DM1 to these cell lines to observe whether there is an increase in anticancer activity. We used a cell viability test to show the cytotoxicity of trastuzumab and T-DM1. Also, we used ELISA and immunofluorescence for HER-2 pathway proteins to understand the mechanism of increased anti-cancer activity.ResultsWe showed that administration of lapatinib for 10 days leads to overexpression of HER-2 receptors on both MCF-7 and HT-29 cells. A significant increase in the cytotoxicity of trastuzumab or T-DM1 was observed after 10 days of lapatinib administration.ConclusionWe named this method the smash method, which is the volleyball term. In volleyball, the ball is raised while low and quickly hits the ground again, just like we do with the HER-2 receptor. The smash method can switch HER-2 negative or HER-2 low tumors into HER-2 overexpressed, iatrogenically. Thus, we can use her2-targeted therapies in all cancer patients instead of a small portion.
dc.description.sponsorshipTurkish Society of Medical Oncology
dc.description.sponsorshipThe authors thank Sivas Cumhuriyet University Medical Faculty Research Center (CUTFAM) and the Turkish Society of Medical Oncology (TTOD) for providing the necessary facilities to conduct this study.
dc.identifier.doi10.1007/s00280-024-04726-9
dc.identifier.issn0344-5704
dc.identifier.issn1432-0843
dc.identifier.issue1
dc.identifier.pmid39714638
dc.identifier.scopus2-s2.0-85212777955
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1007/s00280-024-04726-9
dc.identifier.urihttps://hdl.handle.net/20.500.12418/35629
dc.identifier.volume95
dc.identifier.wosWOS:001382945100002
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofCancer Chemotherapy and Pharmacology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250504
dc.subjectHer-2 overexpression
dc.subjectLapatinib
dc.subjectSmash method
dc.subjectTrastuzumab
dc.titleHER-2 SMASH
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu